Imaging lithium in the brain of people with bipolar disorder
Uses 7 Tesla scans to measure brain lithium in adults with bipolar disorder.
Plain-language title generated from the registry record
Registry title: The Bipolar Lithium Imaging Scan Study.
Key facts
- Where
- Leiden, NetherlandsSee the site
Where in Netherlands
- Leiden University Medical CenterLeiden, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Leiden University Medical Center
- Trial code
- NCT06134349
- Record updated
- 13 December 2024
- Original description
The main goal of this study is to determine if brain lithium-concentrations predict clinical lithium treatment-response. Secondary, to study correlations between intracerebral distribution-patterns of lithium with clinical treatment outcome.Read full original descriptionShow less
The Bipolar Lithium Imaging Scan Study: Imaging Lithium in the Brains of Subjects with Bipolar Disorder
The main goal of this study is to determine if brain lithium-concentrations predict clinical lithium treatment-response. Secondary, to study correlations between intracerebral distribution-patterns of lithium with clinical treatment outcome.
Brain lithium concentrations will be measured using ultra-high field (7 Tesla) lithium magnetic resonance (MR) imaging, which has recently been introduced. Determining lithium-concentrations in the brain has been difficult so far due to lithium's relatively low concentration (compared to protons, which are targeted in conventional MRI). 7T lithium MR imaging has the potential to produce much more detailed MR images compared with previous studies, for the first time. The BLISS study is expected to yield new insights, helping to better understand why clinical lithium response varies between individuals.
Inclusion: age 18 years or above,; a clinical diagnosis of bipolar disorder type I or type II ,; having reached stable therapeutic serum lithium concentrations (reference values 0.6-1.0 mM in age to 65 years; 0.4-0.8 in age 65 years and above) within four weeks prior to study participation, and; provided written informed consent.
Exclusion: drug or alcohol abuse over a period of two weeks prior to study participation, and; insufficient comprehension of the Dutch language,; unable to provide informed consent,; meeting any exclusion criterium for MR imaging.